Research evidence pack
Source-backed valuation visuals
Loading verified market, valuation, and statement data.
2. Company Fundamentals
2.1 Competitiveness
| Metric | Value |
|---|---|
| Operating Margins | 31.62% |
| Profit Margins | 11.83% |
| Return on Equity | 8.31% |
| Return on Assets | 5.69% |
| Free Float | 5.69B |
| Dividend Yield | 7.08% |
| Short Int % Utilisation | 2.85% |
2.2 Growth
| Metric | Value |
|---|---|
| Revenue Growth | 5.4% |
| Free Cash Flow | 12.38B |
| EBITDA | 7.77 (Ratio) |
| Enterprise Value | 197.86B |
| EV/Revenue | 3.12 |
| EV/EBITDA | 7.77 |
Revenue growth of 5.4% indicates steady, moderate expansion.
2.3 Management
| Role | Metric |
|---|---|
| Consensus Rating | N/A |
2.4 Return
| Metric | Value |
|---|---|
| Expected Return (Ann.)* | 17.28% |
| Risk / Std Dev (Ann.)* | 23.37% |
| 1-Year Price Return* | 14.04% |
Latest Market Data (as of 2026-08-14, US Eastern time):
| Metric | Value |
|---|---|
| Last Price | $26.79 |
| 52-Week Range | $23.58 – $28.75 |
| Observation Count | 251 trading days |
The return and risk statistics use daily adjusted closes from the retrieved one-year series and annualise daily moments using 252 trading days. The last price is the latest regular-market price reported for the stated date. Source: Yahoo Finance market data.
2.5 Valuation & Cash Flow
Data status: the verified data fields are incomplete or the WACC requires assumption review. The post does not publish a mechanical UFCF/WACC conclusion for this issuer.
| Available valuation input | Value |
|---|---|
| Last market price | $26.87 |
| Market capitalisation | $153.15B |
| Reported free cash flow | $9.07B |
| FCF yield | 5.93% |
| Net debt / EBITDA | 3.00x |
2.6 Investor-Style Research Screen
| Educational screen | Result |
|---|---|
| Buffett-inspired cash-quality checks | not rated — model suitability or data-integrity condition not met |
| Lynch-inspired balance-and-growth checks | not rated — model suitability or data-integrity condition not met |
Data lineage: Yahoo Finance public market and statement data; retrieval timestamp: 2026-08-17 23:49:03.226733 UTC; latest reported fiscal period: 2025-12-31 00:00:00. A screen result is an evidence flag, not a buy or sell instruction.
us-equity stock equity pfe health-care pharmaceuticals nasdaq